Clinical research on combined chemotherapy of vinorelbine and cisplatin in the treatment of non-small cell lung cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 381-385, 2003.
Article
ي Zh
| WPRIM
| ID: wpr-345883
المكتبة المسؤولة:
WPRO
ABSTRACT
<p><b>BACKGROUND</b>To evaluate the efficacy, side-effects, median survival duration and survival rate of vinorelbine (NVB) combined with cisplatin (DDP) in the treatment of non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>A total of 220 patients with inoperable NSCLC received NVB and DDP combined chemotherapy NVB 25-30 mg/(m²*d) on days 1 and 5 (or 8), DDP 60-80 mg/(m²*d) on day 2. The schedule was repeated every 28 days. The efficacy and side-effects were analysed and followed-up after at least two cycles of chemotherapy.</p><p><b>RESULTS</b>The overall response rate (CR+PR) was 30.9% (68/220). The response rate was 31.3% (51/163) in initial treatment group, and 29.8% (17/57) in retreatment group. The median survival duration was 8.3 months. The 1-, 2- and 3-year survival rates were 39.23%, 19.31% and 6.32%, respectively. The main side-effects were myelosuppression and digestive tract reactions.</p><p><b>CONCLUSIONS</b>Vinorelbine plus cisplatin is an effective and well-tolerated regimen for non small cell lung cancer and myelosuppression is its dose-limiting toxicity.</p>
النص الكامل:
1
الفهرس:
WPRIM
اللغة:
Zh
مجلة:
Chinese Journal of Lung Cancer
السنة:
2003
نوع:
Article